136 related articles for article (PubMed ID: 37383001)
1. Dale DC, Firkin F, Bolyard AA, et al. Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome. Blood. 2020;136(26):2994-3003.
Blood; 2023 Jun; 141(26):3232. PubMed ID: 37383001
[No Abstract] [Full Text] [Related]
2. Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome.
Dale DC; Firkin F; Bolyard AA; Kelley M; Makaryan V; Gorelick KJ; Ebrahim T; Garg V; Tang W; Jiang H; Skerlj R; Beaussant Cohen S
Blood; 2020 Dec; 136(26):2994-3003. PubMed ID: 32870250
[TBL] [Abstract][Full Text] [Related]
3. Genotype-phenotype correlations in WHIM syndrome: a systematic characterization of CXCR4
Zmajkovicova K; Pawar S; Maier-Munsa S; Maierhofer B; Wiest I; Skerlj R; Taveras AG; Badarau A
Genes Immun; 2022 Sep; 23(6):196-204. PubMed ID: 36089616
[TBL] [Abstract][Full Text] [Related]
4. Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma.
Andtbacka RHI; Wang Y; Pierce RH; Campbell JS; Yushak M; Milhem M; Ross M; Niland K; Arbeit RD; Parasuraman S; Bickley K; Yeung CC; Aicher LD; Smythe KS; Gan L
Cancer Res Commun; 2022 Aug; 2(8):904-913. PubMed ID: 36923305
[TBL] [Abstract][Full Text] [Related]
5. Phase 3 randomized trial of mavorixafor, CXCR4 antagonist, in WHIM syndrome.
Badolato R; Alsina L; Azar A; Bertrand Y; Bolyard AA; Dale DC; Deyà-Martinez À; Dickerson KE; Ezra N; Hasle H; Kang HJ; Kiani-Alikhan S; Kuijpers TW; Kulagin A; Langguth D; Levin C; Neth O; Olbrich P; Peake J; Rodina Y; Rutten CE; Shcherbina A; Tarrant TK; Vossen MG; Wysocki CA; Belschner A; Bridger GJ; Chen K; Dubuc S; Hu Y; Jiang H; Li S; MacLeod R; Stewart M; Taveras AG; Yan T; Donadieu J
Blood; 2024 Apr; ():. PubMed ID: 38643510
[TBL] [Abstract][Full Text] [Related]
6. A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy.
Choueiri TK; Atkins MB; Rose TL; Alter RS; Ju Y; Niland K; Wang Y; Arbeit R; Parasuraman S; Gan L; McDermott DF
Invest New Drugs; 2021 Aug; 39(4):1019-1027. PubMed ID: 33507454
[TBL] [Abstract][Full Text] [Related]
7. AMD3100 is a potent antagonist at CXCR4(R334X) , a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome.
McDermott DH; Lopez J; Deng F; Liu Q; Ojode T; Chen H; Ulrick J; Kwatemaa N; Kelly C; Anaya-O'Brien S; Garofalo M; Marquesen M; Hilligoss D; DeCastro R; Malech HL; Murphy PM
J Cell Mol Med; 2011 Oct; 15(10):2071-81. PubMed ID: 21070597
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a new WHIM syndrome mutant reveals mechanistic differences in regulation of the chemokine receptor CXCR4.
Luo J; De Pascali F; Richmond GW; Khojah AM; Benovic JL
J Biol Chem; 2022 Feb; 298(2):101551. PubMed ID: 34973340
[TBL] [Abstract][Full Text] [Related]
9. A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome.
McDermott DH; Velez D; Cho E; Cowen EW; DiGiovanna JJ; Pastrana DV; Buck CB; Calvo KR; Gardner PJ; Rosenzweig SD; Stratton P; Merideth MA; Kim HJ; Brewer C; Katz JD; Kuhns DB; Malech HL; Follmann D; Fay MP; Murphy PM
J Clin Invest; 2023 Oct; 133(19):. PubMed ID: 37561579
[TBL] [Abstract][Full Text] [Related]
10. Low-level Cxcr4-haploinsufficient HSC engraftment is sufficient to correct leukopenia in WHIM syndrome mice.
Gao JL; Owusu-Ansah A; Paun A; Beacht K; Yim E; Siwicki M; Yang A; Liu Q; McDermott DH; Murphy PM
JCI Insight; 2019 Dec; 4(24):. PubMed ID: 31687976
[TBL] [Abstract][Full Text] [Related]
11. WHIM Syndrome-linked CXCR4 mutations drive osteoporosis.
Anginot A; Nguyen J; Abou Nader Z; Rondeau V; Bonaud A; Kalogeraki M; Boutin A; Lemos JP; Bisio V; Koenen J; Hanna Doumit Sakr L; Picart A; Coudert A; Provot S; Dulphy N; Aurrand-Lions M; Mancini SJC; Lazennec G; McDermott DH; Guidez F; Blin-Wakkach C; Murphy PM; Cohen-Solal M; Espéli M; Rouleau M; Balabanian K
Nat Commun; 2023 Apr; 14(1):2058. PubMed ID: 37045841
[TBL] [Abstract][Full Text] [Related]
12. The negative charge of the 343 site is essential for maintaining physiological functions of CXCR4.
Wang L; Xiong Q; Li P; Chen G; Tariq N; Wu C
BMC Mol Cell Biol; 2021 Jan; 22(1):8. PubMed ID: 33485325
[TBL] [Abstract][Full Text] [Related]
13. WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4.
Liu Q; Chen H; Ojode T; Gao X; Anaya-O'Brien S; Turner NA; Ulrick J; DeCastro R; Kelly C; Cardones AR; Gold SH; Hwang EI; Wechsler DS; Malech HL; Murphy PM; McDermott DH
Blood; 2012 Jul; 120(1):181-9. PubMed ID: 22596258
[TBL] [Abstract][Full Text] [Related]
14. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.
McDermott DH; Liu Q; Ulrick J; Kwatemaa N; Anaya-O'Brien S; Penzak SR; Filho JO; Priel DA; Kelly C; Garofalo M; Littel P; Marquesen MM; Hilligoss D; Decastro R; Fleisher TA; Kuhns DB; Malech HL; Murphy PM
Blood; 2011 Nov; 118(18):4957-62. PubMed ID: 21890643
[TBL] [Abstract][Full Text] [Related]
15. Mesenchymal Stem/Stromal Cells Overexpressing CXCR4
Bidkhori HR; Bahrami AR; Farshchian M; Heirani-Tabasi A; Mirahmadi M; Hasanzadeh H; Ahmadiankia N; Faridhosseini R; Dastpak M; Shabgah AG; Matin MM
Cell Transplant; 2021; 30():9636897211054498. PubMed ID: 34807749
[TBL] [Abstract][Full Text] [Related]
16. Filamin A interaction with the CXCR4 third intracellular loop regulates endocytosis and signaling of WT and WHIM-like receptors.
Gómez-Moutón C; Fischer T; Peregil RM; Jiménez-Baranda S; Stossel TP; Nakamura F; Mañes S
Blood; 2015 Feb; 125(7):1116-25. PubMed ID: 25355818
[TBL] [Abstract][Full Text] [Related]
17. The CXCR4 mutations in WHIM syndrome impair the stability of the T-cell immunologic synapse.
Kallikourdis M; Trovato AE; Anselmi F; Sarukhan A; Roselli G; Tassone L; Badolato R; Viola A
Blood; 2013 Aug; 122(5):666-73. PubMed ID: 23794067
[TBL] [Abstract][Full Text] [Related]
18. The
Pansy K; Feichtinger J; Ehall B; Uhl B; Sedej M; Roula D; Pursche B; Wolf A; Zoidl M; Steinbauer E; Gruber V; Greinix HT; Prochazka KT; Thallinger GG; Heinemann A; Beham-Schmid C; Neumeister P; Wrodnigg TM; Fechter K; Deutsch AJ
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554271
[TBL] [Abstract][Full Text] [Related]
19. A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.
McDermott DH; Liu Q; Velez D; Lopez L; Anaya-O'Brien S; Ulrick J; Kwatemaa N; Starling J; Fleisher TA; Priel DA; Merideth MA; Giuntoli RL; Evbuomwan MO; Littel P; Marquesen MM; Hilligoss D; DeCastro R; Grimes GJ; Hwang ST; Pittaluga S; Calvo KR; Stratton P; Cowen EW; Kuhns DB; Malech HL; Murphy PM
Blood; 2014 Apr; 123(15):2308-16. PubMed ID: 24523241
[TBL] [Abstract][Full Text] [Related]
20. TREC Screening for WHIM Syndrome.
Evans MO; Petersen MM; Khojah A; Jyonouchi SC; Edwardson GS; Khan YW; Connelly JA; Morris D; Majumdar S; McDermott DH; Walter JE; Murphy PM
J Clin Immunol; 2021 Apr; 41(3):621-628. PubMed ID: 33415666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
